Jianan Lei^*, Zhuona Ni, Ruidi Zhang

Oncology Research, Vol.33, No.11, pp. 3347-3373, 2025, DOI:10.32604/or.2025.067445 - 22 October 2025

Abstract This review aims to explore the development, challenges, and future directions of UCAR cell therapy as a scalable alternative to autologous CAR-T for cancer treatment. Consequently, limitations of autologous CAR-T, including long production, variable quality, and cost, drive off-the-shelf UCAR development to standardize manufacturing and improve access. Current UCAR-T cell strategies focus on mitigating the risks of graft-vs.-host disease and host-vs.-graft rejection through advanced gene editing technologies, including clustered regularly interspaced short palindromic repeat-associated system Cas9-mediated knockout of the T cell receptor, human leukocyte antigen, and cluster of differentiation 52 (CD52). Beyond conventional T cells, cell… More >

Sotirios Charalampos Diamantoudis^1,#,*, Androulla N. Miliotou^2,#, Eleftheria Galatou², Stergiani Telliou³, Konstantinos Sideris⁴, Nikolaos Grigoriadis¹, Ioannis S. Vizirianakis^1,2,*

BIOCELL, Vol.49, No.10, pp. 1799-1858, 2025, DOI:10.32604/biocell.2025.067216 - 22 October 2025

Abstract Hematological cancer stem cells (HCSCs) is a subpopulation of cells within hematological cancers that, through their characteristics, enhance malignancy and render their therapy more challenging. By uncovering the underlying mechanisms behind characteristic properties such as self-renewal, immune evasion, and conventional therapy resistance, as well as the major differences between other cancers and physiological cells, new and alternative targets can be assessed for use in existing and novel immunotherapeutic interventions. Through the evaluation of the existing literature, one can realize that there have already been several studies addressing the use of stem cell transplantation (SCT), monoclonal More > Graphic Abstract

Norbert Nass^1,2,#, Mohamad-Kamal Yaakoub^1,#, Alexandra-Victorita Simion³, Hartmut Kroll⁴, Sabine Westphal³, Judith Pannier¹, Gerhard Behre^1,*

Oncology Research, Vol.33, No.10, pp. 2923-2935, 2025, DOI:10.32604/or.2025.067561 - 26 September 2025

Abstract Background: Patients with hemato-oncological malignancies may respond insufficiently to vaccination, especially in terms of antibody titer. The antibody response depends on the type of malignancy as well as the type and timing of treatment. We intended to evaluate this using real-world data from patients of our regional hospital. This study also considers the role of immune status, including T-cell activation markers, in predicting vaccination success. Methods: Seventeen patients of our hospital having a hematological malignancy were included in this study, including myeloma, lymphoma, as well as acute myeloid leukemia (AML) and chronic lymphoid leukemia (CLL).… More >

Ting Wei^1,2,#, Pengli Wei^2,3,#, Yalei Wang^1,2, Yaqiu Mao^2,3, Jian Yan², Xiaotong Hu², Zhenze Qi², Xu Cai², Changkai Jia², Zhiyuan Zhao², Bingkun Li², Min Qiao², Yaxin Zou^2,3, Tingting Yang⁴, Shiyang Sun², Xuesong Feng³, Pengyun Li^2,*, Hongzhou Shang^1,*, Zhibing Zheng²

Oncology Research, Vol.33, No.10, pp. 2981-3006, 2025, DOI:10.32604/or.2025.065123 - 26 September 2025

Abstract Objectives: Immunomodulatory drugs (IMiDs), functioning as molecular glue degraders, have been approved for treating various hematological malignancies; however, the inevitable acquired drug resistance resulting from their skeletal similarity and hematological toxicities poses significant obstacles to their clinical treatment. The study aimed to develop degraders with potent efficiency and low toxicity. Methods: Phenotypic profiling, elaborate structure-activity relationships (SAR), rational drug design and degradation profiles investigations, quantitative proteomics analysis and cell-based functional studies, and pharmacokinetic studies were conducted to develop more potent degraders. Results: This study developed novel CRBN-binding moieties through methylene deletion in lenalidomide’s isoindole core. Lead… More > Graphic Abstract

Osama M. Alshehri¹, Ahmad Shaf^2,*, Muhammad Irfan^3,*, Mohammed M. Jalal⁴, Malik A. Altayar⁴, Mohammed H. Abu-Alghayth⁵, Humood Al Shmrany⁶, Tariq Ali⁷, Toufique A. Soomro⁸, Ali G. Alkhathami⁹

CMES-Computer Modeling in Engineering & Sciences, Vol.144, No.1, pp. 1165-1196, 2025, DOI:10.32604/cmes.2025.067150 - 31 July 2025

Abstract Background: Accurate classification of normal blood cells is a critical foundation for automated hematological analysis, including the detection of pathological conditions like leukemia. While convolutional neural networks (CNNs) excel in local feature extraction, their ability to capture global contextual relationships in complex cellular morphologies is limited. This study introduces a hybrid CNN-Transformer framework to enhance normal blood cell classification, laying the groundwork for future leukemia diagnostics. Methods: The proposed architecture integrates pre-trained CNNs (ResNet50, EfficientNetB3, InceptionV3, CustomCNN) with Vision Transformer (ViT) layers to combine local and global feature modeling. Four hybrid models were evaluated on… More >

Tengyue Li^1,*, Shuangli Song¹, Jiaming Zhou², Simon Fong^2,3, Geyue Li⁴, Qun Song³, Sabah Mohammed⁵, Weiwei Lin⁶, Juntao Gao⁷

CMC-Computers, Materials & Continua, Vol.84, No.1, pp. 1711-1730, 2025, DOI:10.32604/cmc.2025.062489 - 09 June 2025

Abstract Hematoxylin and Eosin (H&E) images, popularly used in the field of digital pathology, often pose challenges due to their limited color richness, hindering the differentiation of subtle cell features crucial for accurate classification. Enhancing the visibility of these elusive cell features helps train robust deep-learning models. However, the selection and application of image processing techniques for such enhancement have not been systematically explored in the research community. To address this challenge, we introduce Salient Features Guided Augmentation (SFGA), an approach that strategically integrates machine learning and image processing. SFGA utilizes machine learning algorithms to identify… More >

Gabrielle R. Yankelevich¹, Kale Moreland², Makayla M. Swancutt², Robert L. Grubb¹

Canadian Journal of Urology, Vol.31, No.6, pp. 12035-12044, 2024

Abstract Introduction: We report the first scoping review of the clinical urologic literature for photodynamic therapy (PDT) among multiple urologic malignancies.
Materials and methods: A scoping review using Medline and Embase was performed for treatment of urologic malignancies with PDT.
Results: There were 84 papers included with the majority involving bladder and prostate cancer. Upper tract urothelial cancer (UTUC) only comprised three publications and there was no clinical data for renal or testicular cancer. Utilizing PDT in prostate cancer led to a negative biopsy rate of 30%-100%. Bladder cancer treatment with PDT had a 3-month complete response rate of More >

EGOR V. BATOROV^1,2,*, ALISA D. INESHINA², TATIANA A. ARISTOVA³, VERA V. DENISOVA³, SVETLANA A. SIZIKOVA³, DARIA S. BATOROVA³, GALINA Y. USHAKOVA³, EKATERINA Y. SHEVELA¹, ELENA R. CHERNYKH¹

Oncology Research, Vol.32, No.10, pp. 1575-1587, 2024, DOI:10.32604/or.2024.047893 - 18 September 2024

Abstract Background: Immune checkpoint ligand-receptor interactions appear to be associated with multiple myeloma (MM) progression. Simultaneously, previous studies showed the possibility of PD-1 and TIM-3 expression on T cells upon stimulation with common γ-chain family cytokines in vitro and during homeostatic proliferation. The aim of the present work was to study the impact of homeostatic proliferation on the expansion of certain T cell subsets up-regulating PD-1 and TIM-3 checkpoint molecules. Methods: The expression of CD25, CD122, CD127 common γ-chain cytokine receptors, phosphorylated signal transducer and activator of transcription-5 (pSTAT5) and eomesodermin (EOMES) was comparatively assessed with flow… More >

MINGYUE HUANG^1,#, JUNFEI DAI^1,#, XIANLIANG ZHONG², JIN WANG², JIANZHONG XU², BO DU^2,*

BIOCELL, Vol.48, No.6, pp. 889-896, 2024, DOI:10.32604/biocell.2024.050097 - 10 June 2024

Abstract Chronic subdural hematoma (CSDH) is a disease characterized by capsuled blood products that progressively occupy the intracranial space, causing intracranial hypertension and compression in the brain. CSDH frequently occurs in all demographics, especially in the elderly, but the pathogenesis of CSDH remains unclear. In this review, we discuss the origin, development, and current treatment strategies of CSDH. For the first time, we analyzed the cellular and molecular compositions of hematoma membranes with a focus on neomembrane formation, a complex early-stage interactive event in hematoma pathogenesis. We hypothesize that in patients with CSDH, dural border cells… More >

ZHIGANG XIA^1,#, MENGYAO TIAN^1,#, YUCAI CHENG¹, WENFANG YI¹, ZEFAN DU^1,2, TIANWEN LI^1,2, YUCHEN WEN¹, LINDI LI^1,2, YONG LIU^1,2,*, CHUN CHEN^1,*

Oncology Research, Vol.32, No.6, pp. 1109-1118, 2024, DOI:10.32604/or.2024.049792 - 23 May 2024

Abstract Background: Chimeric antigen receptor T (CAR-T) cell therapy has achieved marked therapeutic success in ameliorating hematological malignancies. However, there is an extant void in the clinical guidelines concerning the most effective chemotherapy regimen prior to chimeric antigen receptor T (CAR-T) cell therapy, as well as the optimal timing for CAR-T cell infusion post-chemotherapy. Materials and Methods: We employed cell-derived tumor xenograft (CDX) murine models to delineate the optimal pre-conditioning chemotherapy regimen and timing for CAR-T cell treatment. Furthermore, transcriptome sequencing was implemented to identify the therapeutic targets and elucidate the underlying mechanisms governing the treatment regimen.… More >